{
  "source": "PA-Med-Nec-Orilissa.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 2152-8\nProgram Prior Authorization/Medical Necessity\nMedication Orilissa® (elagolix)\nP&T Approval Date 10/2018, 10/2019, 9/2020, 9/2021, 9/2022, 2/2023, 2/2024, 2/2025\nEffective Date 5/1/2025\n1. Background:\nOrilissa (elagolix) is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated\nfor the management of moderate to severe pain associated with endometriosis.\n2. Coverage Criteriaa:\nA. Orilissa 150 mg\n1. Initial Authorization\na. Orilissa 150 mg will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe pain associated with endometriosis\n-AND-\n(2) Failure after a three-month trialb (e.g., inadequate pain relief), contraindication or\nintolerance of two analgesics (e.g., ibuprofen, meloxicam, naproxen)\n-AND-\n(3) Failure after a three-month trialb, contraindication, or intolerance to one of the\nfollowing:\n(a) Hormonal contraceptives\n(b) Progestins [e.g., norethindrone (generic Aygestin®)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Obstetrics/Gynecologist (OB/GYN)\n(b) Reproductive endocrinologist\nAuthorization will be issued for 12 months\n2. Reauthorization\na. Orilissa 150 mg will be approved based on all of the following criteria:\n© 2025 UnitedHealthcare Services Inc.\n1\n(1) Documentation of positive clinical response to therapy\n(2) Impact to bone mineral density has been considered\n(3) Treatment duration has not exceeded a total of 24 months\nAuthorization will be issued for 12 months up to a maximum treatment duration of 24\nmonths\nNOTE: Orilissa 150 mg once daily is indicated for a maximum treatment duration of 24\nmonths\nB. Orilissa 200 mg\n1. Initial Authorization\na. Orilissa 200 mg will be approved based on all of the following criteria:\n(1) Diagnosis of moderate to severe pain associated with endometriosis\n-AND-\n(2) Failure after a three-month trialb (e.g., inadequate pain relief), contraindication or\nintolerance of ",
    "lowing criteria:\n(1) Diagnosis of moderate to severe pain associated with endometriosis\n-AND-\n(2) Failure after a three-month trialb (e.g., inadequate pain relief), contraindication or\nintolerance of two analgesics (e.g., ibuprofen, meloxicam, naproxen)\n-AND-\n(3) Failure after a three-month trialb, contraindication, or intolerance to one of the\nfollowing:\n(a) Hormonal contraceptives\n(b) Progestins [e.g., norethindrone (generic Aygestin)]\n-AND-\n(4) Prescribed by or in consultation with one of the following:\n(a) Obstetrics/Gynecologist (OB/GYN)\n(b) Reproductive endocrinologist\nAuthorization will be issued for 6 months\nNOTE: Orilissa 200 mg twice daily is indicated for a maximum treatment duration of 6\nmonths\na State mandates may apply. Any federal regulatory requirements and the member specific benefit\nplan coverage may also impact coverage criteria. Other policies and utilization management\nprograms may apply.\nb For Connecticut, Kentucky and Mississippi business, only a 30 day trial will be required.\n© 2025 UnitedHealthcare Services Inc.\n2\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Orilissa [package insert]. North Chicago, IL: AbbVie Inc.; June 2023.\n2. Taylor H, Giudice L, Lessey B, et al. Treatment of endometriosis-associated pain with\nelagolix, an oral GnRH antagonist. N Engl J Med 2017; 377:28-40.\n3. The American College of Obstetricians and Gynecologists. Management of endometriosis.\nPractice Bulletin 114. July 2010 (Reaffirmed 2018).\nProgram Prior Authorization/Medical Necessity – Orilissa\nChange Control\nDate Change\n10/2018 New program\n10/2019 Annual review. No changes.\n9/2020 Annual review. Updated references.\n9/2021 Annual review. Updated ",
    "or Authorization/Medical Necessity – Orilissa\nChange Control\nDate Change\n10/2018 New program\n10/2019 Annual review. No changes.\n9/2020 Annual review. Updated references.\n9/2021 Annual review. Updated CT and KY trial language. Updated references.\n9/2022 Annual review. Updated mandate language to include Mississippi.\n2/2023 Removed the criteria that patient is premenopausal.\n2/2024 Annual review. Updated failure language. Updated state mandate\nlanguage. Updated authorization duration. Updated references.\n2/2025 Annual review. No changes.\n© 2025 UnitedHealthcare Services Inc.\n3"
  ]
}